The gene vaccination in cancer (GVC) meeting offered the opportunity to continue and strengthen the existing national and international collaborations between basic scientists, clinical researchers and scientists in industry to overcome obstacles in gene vaccination against cancer. The 2013 GVC meeting covered the following topics: (1) new technologies for gene vaccination; (2) emerging targets for cancer vaccines; (3) therapeutic vaccination against human papillomavirus (HPV)-dependent diseases; (4) preclinical challenges; (5) veterinary applications of gene vaccination in cancer; (6) in vivo gene-electro-transfer: from technology development to clinical applications.
Second Ascoli Piceno conference on gene vaccination in cancer (GVC), Ascoli Piceno, Italy, October 9–11, 2013
MARCHINI, Cristina;AMICI, Augusto;
2014-01-01
Abstract
The gene vaccination in cancer (GVC) meeting offered the opportunity to continue and strengthen the existing national and international collaborations between basic scientists, clinical researchers and scientists in industry to overcome obstacles in gene vaccination against cancer. The 2013 GVC meeting covered the following topics: (1) new technologies for gene vaccination; (2) emerging targets for cancer vaccines; (3) therapeutic vaccination against human papillomavirus (HPV)-dependent diseases; (4) preclinical challenges; (5) veterinary applications of gene vaccination in cancer; (6) in vivo gene-electro-transfer: from technology development to clinical applications.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
